This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast
The Following drugs will be use in combination with Ruxolinitinib.
Paclitaxel (also called Taxol)
Doxorubicin also called Adriamycin
Cyclophosphamide, also called Cytoxan
This is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness
of an investigational intervention to learn whether the intervention works in treating a
specific disease. "Investigational" means that the intervention is being studied.
The FDA (U.S. Food and Drug Administration) has not approved Ruxolitinib for Inflammatory
Breast Cancer (IBC), but is has been approved for other uses.
Ruxolitinib is a newly discovered drug that has been shown to block a pathway (called the
IL6/JAK/Stat pathway) that may be important in cancer, including triple negative inflammatory
breast cancer. Ruxolitinib brings proteins groups together, which can result in gene (DNA)
changes. These DNA changes may stop cancer cells from growing.
Paclitaxel (also called Taxol), Doxorubicin and Cyclophosphamide (also called Adriamycin and
Cytoxan, ("AC")) are drugs FDA approved for breast cancer patients. They have been shown to
result in death of cancer cells when given as preoperative treatment of women with
inflammatory breast cancer (IBC). Laboratory studies have shown that Ruxolitinib may make
Paclitaxel more effective.
In this research study, the investigators are evaluating Ruxolitinib in combination with
Paclitaxel followed by the standard chemotherapy, AC. Researchers will also evaluate how the
IL6/JAK/Stat pathway is affected by this combination of drugs by studying biopsies and
Inflammatory Breast Cancer,
inflammatory breast cancers
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.